Director/PDMR Shareholding

Dechra Pharmaceuticals PLC
16 October 2023
 



Dechra Logo

 

 

16 October 2023

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

 

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

 

 

Dechra Pharmaceuticals PLC announces that on 13 October 2023, the following PDMRs acquired ordinary shares of 1p each in the Company pursuant to awards granted to them on 22 September 2020 under the Dechra Pharmaceuticals PLC Long Term Incentive Plan (the LTIP). The vesting of the awards was subject to the achievement of performance conditions which were satisfied to the extent that the awards vested at 16.4%.   

 

Name

Capacity

Shares acquired

Total beneficial shareholding following this announcement

Percentage of issued share capital

Tony Griffin

Director

1,730

38,779

0.034%

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

 

Notification of Dealing Form

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Tony Griffin

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

 Acquisition of shares pursuant to the Company's Long Term Incentive Plan

 

c)

Price(s) and volumes(s)

Price(s)

£nil

Volume(s)

1,730

d)

Aggregated information

-    Aggregate volume

-    Price

 

 

N/A

e)

Date of the transaction

13 October 2023

f)

Place of the transaction

Outside a trading venue

 

 

 

For further information, please contact:

 

Melanie Hall, Company Secretary                          

Telephone number: 01606 814730

 

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings